Commerce Bank Acquires 108 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Commerce Bank raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,199 shares of the company’s stock after acquiring an additional 108 shares during the period. Commerce Bank’s holdings in Neurocrine Biosciences were worth $484,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new stake in Neurocrine Biosciences in the second quarter valued at about $28,000. Innealta Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. acquired a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at approximately $32,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $35,000. Finally, Blue Trust Inc. grew its holdings in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $127.91 on Wednesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.52 and a fifty-two week high of $157.98. The firm has a market capitalization of $12.95 billion, a PE ratio of 34.29 and a beta of 0.35. The company’s 50-day moving average is $118.83 and its 200-day moving average is $131.74.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Guggenheim increased their target price on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Citigroup boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.